Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199984 | 0.98 | CYP11B2 (0.43) | CYP11B2OPRL1CHRNB2CHRNA4GAA | |
| SCHEMBL22199985 | 0.98 | CYP11B2 (0.43) | CYP11B2OPRL1CHRNB2CHRNA4GAA | |
| SCHEMBL16132330 | 0.93 | OPRL1 (0.39) | OPRL1CHRNB2CHRNA4RBP4CYP17A1 | |
| SCHEMBL8139062 | 0.78 | OPRL1 (0.40) | CYP11B2OPRL1CHRNB2CHRNA4RBP4 | |
| SCHEMBL21757517 | 0.76 | OPRL1 (0.49) | CYP11B2OPRL1CHRNB2CHRNA4TDO2 | |
| SCHEMBL21757521 | 0.74 | OPRL1 (0.48) | CYP11B2OPRL1CHRNB2CHRNA4TDO2 | |
| SCHEMBL21757505 | 0.74 | OPRL1 (0.48) | CYP11B2OPRL1CHRNB2CHRNA4TDO2 | |
| SCHEMBL27295140 | 0.72 | CYP11B2 (0.44) | CYP11B2OPRL1CHRNB2CHRNA4TDO2 | |
| SCHEMBL16335849 | 0.72 | HTR2C (0.44) | GAARBP4 | |
| SCHEMBL21973762 | 0.70 | CYP11B2 (0.43) | CYP11B2OPRL1CHRNB2CHRNA4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014933-B2 | Non-peptide opioid receptor modulators | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200216458-A1 | NON-PEPTIDE OPIOID RECEPTOR MODULATORS | VIRGINIA COMMONWEALTH UNIVERSITY | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014933-B2 | Non-peptide opioid receptor modulators | OPRM1, OPRL1, OPRK1 | CYP11B2 3720/4885OPRL1 2/4885CHRNB2 271/4885 |
| US-20200216458-A1 | NON-PEPTIDE OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | CYP11B2 3720/4885OPRL1 2/4885CHRNB2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.